Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 5/20 | 0.42 |
| ▸ | TDO2 | P48775 | 4/20 | 0.42 |
| ▸ | IDO2 | Q6ZQW0 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30639084 | 1.00 | ADORA2A (0.44) | ADORA2AADORA1APAF1IDO1TDO2 | |
| SCHEMBL26614297 | 0.90 | APAF1 (0.46) | ADORA2AADORA1APAF1IDO1TDO2 | |
| SCHEMBL26614187 | 0.86 | APAF1 (0.53) | ADORA2AADORA1APAF1IDO1TDO2 | |
| SCHEMBL30639059 | 0.86 | APAF1 (0.53) | ADORA2AADORA1APAF1IDO1TDO2 | |
| SCHEMBL26614087 | 0.84 | IDO1 (0.50) | APAF1IDO1TDO2IDO2 | |
| SCHEMBL30639062 | 0.84 | IDO1 (0.50) | APAF1IDO1TDO2IDO2 | |
| SCHEMBL30639058 | 0.83 | APAF1 (0.53) | APAF1IDO1TDO2IDO2MAPK14 | |
| SCHEMBL26614131 | 0.83 | APAF1 (0.53) | APAF1IDO1TDO2IDO2MAPK14 | |
| SCHEMBL31382855 | 0.82 | APAF1 (0.49) | APAF1IDO1TDO2IDO2MAPK14 | |
| SCHEMBL26614226 | 0.82 | APAF1 (0.49) | APAF1IDO1TDO2IDO2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. | 2025-05-29 | — | — | US | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | IDO2, IDO1, TPSB2 | ADORA2A 200/4885ADORA1 1506/4885APAF1 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.